Skip to content
Helping patients reclaim a life of possibility
Clear
Search
Menu
About us
Contact us
Myeloma and AL Amyloidosis
About myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
European Young Myeloma Patients Group
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
European Myeloma Day
News
Myeloma and AL Amyloidosis
About myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
European Young Myeloma Patients Group
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
European Myeloma Day
News
Year: 2023
T2EVOLVE and QUALITOP launch European patient survey on CAR-T treatment
Myeloma
1 March 2023
Daratumumab approved for first line treatment in Israel
MPE
,
Myeloma
30 January 2023
Study shows the importance of vaccination for myeloma patients
Myeloma
26 January 2023
←
1
2
3
4
Go to Top
About MPE
Our members
Our board and staff
Medical Advisory Committee
Our Strategic Goals
Our funding
Get involved in MPE activities
Become a member
Contact us
Myeloma and AL Amyloidosis
About myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
News
European Myeloma Day
Clear
Search
PopUp
Name
This field is for validation purposes and should be left unchanged.
I am a
*
Patient
Patient advocate
Caregiver
Doctor
